TTWM
TEVA icon

TCV Trust & Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

TCV Trust & Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-16,000
Closed -$120K – 195
2022
Q2 		$120K Hold
16,000
– – 0.01% 196
2022
Q1 		$150K Hold
16,000
– – 0.02% 204
2021
Q4 		$128K Buy
+16,000
New +$144K 0.01% 207
2014
Q2 		– Sell
-3,980
Closed -$210K – 176
2014
Q1 		$210K Sell
3,980
-4,125
-51% -$191K 0.04% 164
2013
Q4 		$325K Sell
8,105
-69,699
-90% -$2.74M 0.06% 138
2013
Q3 		$2.94M Sell
77,804
-1,438
-2% -$56.1K 0.57% 59
2013
Q2 		$3.11M Buy
+79,242
New +$3.09M 0.64% 55

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

TCV Trust & Wealth Management's TEVA Position: Q3 2022 in Review

TCV Trust & Wealth Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2022, closing a stake of 16,000 shares — an estimated $120K sold.

TCV Trust & Wealth Management first reported a position in TEVA in Q2 2013 and held it in 7 quarters. The position peaked at $3.11M in Q2 2013. 430 funds tracked by Wall St. Rank hold TEVA as of Q3 2022.

  • TCV Trust & Wealth Management reported no remaining Teva Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • TCV Trust & Wealth Management sold 16,000 Teva Pharmaceuticals shares in Q3 2022, an estimated $120K.
  • TCV Trust & Wealth Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 7 quarters.
  • TCV Trust & Wealth Management's Teva Pharmaceuticals position peaked at $3.11M in Q2 2013.
  • 430 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2022.

Based on TCV Trust & Wealth Management's 13F filing for Q3 2022, filed 31 Oct 2022.